Susan Hill, Mestag CEO
J&J, GV back a new single-cell approach for tackling inflammatory diseases and hacking the tumor microenvironment
Most biotechs trying to tackle inflammatory disorders like IBD or attempting to boost the potency of immunotherapies for cancer have focused, logically, on targeting, blocking …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.